Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals reported strong first-quarter 2026 results, with total revenues of $1.07 billion, up 19% year over year, and GAAP diluted EPS of $4.43 versus a loss a year ago. Non-GAAP adjusted EPS was $6.34, and cash from operations reached $408 million.
Growth was driven by key products, including Xywav (up 18% to $408 million), Epidiolex/Epidyolex (up 15% to $249.8 million) and Zepzelca (up 60% to $101 million), plus initial Modeyso sales. The company ended March 31, 2026 with $2.9 billion in cash, cash equivalents and investments and $5.4 billion in long-term debt principal.
Jazz completed the sale of a Rare Pediatric Disease Priority Review Voucher for gross proceeds of $200 million (50% to Jazz), and reaffirmed its full-year 2026 total revenue guidance of $4.25–$4.5 billion along with both GAAP and non-GAAP margin and expense outlook.
Jazz Pharmaceuticals (Rule 144 notice): The filing reports sales of restricted common stock in lots of 6,000 shares. Two sale entries are shown with trade dates 03/03/2026 and 04/01/2026, each for 6,000 shares, with numeric amounts listed alongside those rows.
Jazz Pharmaceuticals PLC ownership filing shows Vanguard Capital Management reports beneficial ownership of 3,103,522 shares of common stock, representing 5.04% of the class. The filing lists sole voting power for 455,189 shares and sole dispositive power over 3,103,522 shares. The signature date on the filing is 04/30/2026.
Jazz Pharmaceuticals plc filed an Amendment No. 1 to its 2025 annual report to add Part III information normally drawn from its proxy, update the cover page and exhibit list, and provide new CEO/CFO certifications. The company reported an aggregate market value of non‑affiliate equity of about $6.25 billion as of June 30, 2025, and 62,738,815 ordinary shares outstanding as of April 15, 2026.
Jazz highlights record 2025 performance with strong product sales, including Xywav $1,657.0 million and Epidiolex/Epidyolex $1,059.2 million, plus oncology contributions from Zepzelca, Rylaze/Enrylaze, Modeyso and Ziihera. The board describes a pay‑for‑performance design: 2025 bonuses funded at 150% of target based on corporate goals, while 2023–2025 PSUs paid at 94% of target after operational scoring and relative TSR adjustments.
The amendment details a staggered board, refreshed committee memberships and extensive biopharma, financial and governance experience among directors and executives. It also outlines executive incentives tied to multi‑year commercial, pipeline and capital deployment objectives, supported by stock ownership guidelines, a clawback policy, insider‑trading controls and change‑in‑control and severance plans.
Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 ordinary shares of the company in open-market transactions. The sales occurred on 2026-04-01 at weighted average prices of $190.2220, $190.9383 and $191.7447 per share. According to a footnote, these trades were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was not discretionary. After the transactions, Cozadd directly owned 384,682 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals proposed sale notice (Form 144): A notice lists a proposed sale of 6,000 shares of Common Stock with a transaction date shown as 04/01/2026 and Nasdaq as the market. The filing also records a prior sale of 6,000 shares on 03/03/2026 for $1,118,613.32.
Jazz Pharmaceuticals PLC: The Vanguard Group files an amended Schedule 13G/A reporting 0 shares beneficially owned and 0% of the common stock.
The amendment states that on January 12, 2026 The Vanguard Group, Inc. completed an internal realignment and certain subsidiaries will now report holdings separately in reliance on SEC Release No. 34-39538.
Jazz Pharmaceuticals director Bruce C. Cozadd reported a tax-related share disposition. On the vesting of previously granted restricted stock units, 15,114 Ordinary Shares were withheld at $188.69 per share to satisfy tax obligations, reducing his directly held stake to 390,682 Ordinary Shares. This Form 4 reflects a tax-withholding transaction rather than an open-market trade.
Jazz Pharmaceuticals plc Executive Vice President and Chief Financial Officer Philip L. Johnson reported a tax-related share disposition. On March 5, 2026, 2,615 ordinary shares were withheld at $188.69 per share to cover tax obligations from the vesting of previously granted restricted stock units. After this withholding, he directly held 59,608 ordinary shares.
Jazz Pharmaceuticals plc SVP, Technical Operations Mary Elizabeth Henderson reported a tax-related share disposition. On March 5, 2026, she disposed of 1,394 ordinary shares to satisfy tax obligations from vesting restricted stock units, at a weighted average price of $186.747 per share.
The shares were sold in multiple transactions at prices ranging from $186.1633 to $186.7558. After these transactions, Henderson directly owned 27,334 ordinary shares of Jazz Pharmaceuticals.